Ultra-Rapid Lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison to Humalog® in Japanese patients with type 1 diabetes.
Ultra-Rapid Lispro (URLi) is a novel ultra-rapid mealtime insulin. This study compared the pharmacokinetic and glucodynamic profiles, safety, and tolerability of URLi and lispro (Humalog®) in Japanese patients with type 1 diabetes mellitus (T1DM). This was a phase 1, single center, randomized, patient- and investigator-blind, 2-period, crossover study. Thirty-one patients received a single subcutaneous 15-U dose of URLi or lispro before undergoing a euglycemic clamp procedure. Primary pharmacokinetic endpoints: time to early half-maximal drug concentration (early 50% tmax ) and area under the concentration versus time curve from 0 to 30 minutes (AUC[0-30min]) ) } ) post dose. Glucodynamic endpoints: time to early half-maximal glucose infusion rate before time to maximum glucose infusion rate (early 50% tRmax ), and time to onset of insulin action (Tonset ). URLi showed accelerated insulin lispro absorption compared to lispro as indicated by a decrease of 56% (URLi: 10.2 minutes, lispro: 23.3 minutes) (p<.0001) in the early 50% tmax and a 2.4-fold increase in AUC(0-30min) (p<.0001). The duration of insulin lispro exposure was 88 minutes shorter following URLi administration compared to lispro. URLi reduced early 50% tRmax and Tonset significantly compared to lispro. The glucose infused within the first 30 minutes of the clamp was 2.16-fold greater with URLi compared to lispro. There was no difference in total exposure or glucose infused between treatments. All treatment-emergent adverse events were mild/moderate in severity. In Japanese T1DM patients, URLi demonstrated accelerated insulin lispro absorption, reduced late exposure, overall shorter duration, and faster early insulin action compared to lispro.